2 terminated, 1 recruiting, 1 withdrawn. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Metastatic Breast Adenocarcinoma: new trials by email Literature Review of Metastatic Breast Adenocarcinoma trials Research Report on Metastatic Breast Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer Best Practice, Biopsy, Biospecimen Collection - Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma | Not applicable | Withdrawn | City of Hope Medical Center | 2022-07-03 | 2022-06-09 | |
| A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 54 | 2020-09-23 | 2026-07-31 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer CR1447 - Metastatic Breast Adenocarcinoma, Breast Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 29 | 2016-06-14 | 2023-06-27 |
Breast Neoplasms (3)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Biopsy (3) · Magnetic Resonance Spectroscopy (2) · 2C4 antibody (1) · 4,17 beta-dihydroxy-4-androstene-3-one (1) · CT-P6 (1) · Docetaxel (1) · Ogivri (1) · Ontruzant (1) · PF-05280014 (1) · Paclitaxel (1) · Practice Guidelines as Topic (1) · Specimen Handling (1) · Standard of Care (1) · Taxes (1) · Trastuzumab (1)
City of Hope Medical Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Swiss Cancer Institute (1)
United States (2) · Canada (1) · Switzerland (1)
Charles E Geyer (1) · Marcus Vetter, MD (1) · Siddhartha Yadav, MD (1) · Yuan Yuan (1)
P30CA033572 (1), U10CA180868 (1)